In memory of Daniel Birnbaum
17 October 2024
Interview with Rima Kochman, doctoral student in the Coulon team
25 November 2024
Once again, CRCM members have been very productive, with no fewer than 26 articles published in the last 5 months, despite the summer period. All have contributed to significant advances in cancer research.
We thought it would be interesting to present them and highlight some of these projects to show the diversity and impact of the research carried out at CRCM.
Doctoral student thesis projects
First of all, there are the articles corresponding to the thesis projects of the laboratory’s doctoral students:
– they are still in their thesis, as is the case of Rima Kochman from the Coulon team (Publication: “Heterozygous RPA2 variant as a novel genetic cause of telomere biology disorders”)
– or if they finished their thesis a few months ago, such as :
– Dr Julien Grenier of the Aurrand-Lions team (Publication: “Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML”).
– or Dr Vladimir Laletin of the Nunès/Devilliers team (Publication: “DOK1 and DOK2 regulate CD8 T cell signaling and memory formation without affecting tumor cell killing”).
These different studies respectively establish the biological and/or pathological role of replication protein A2 (RPA2) in telomere regulation, the adhesion molecule JAM-C in leukemic stem cells, and the docking proteins DOK1 and DOK2 in T lymphocytes.
But also translational studies
In parallel with this basic research, translational studies are also carried out.
They have led, for example, to the development of a new therapeutic antibody targeting Nectin-4 by Marc Lopez’s group within the Predictive Oncology team and in collaboration with the Immunity and Cancer team (Publication: “ETx-22: a novel nectin-4-directed antibody drug conjugate, demonstrates safety and potent antitumor activity in low nectin-4 expressing tumors”).
This work was the subject of an article and interview with Marc in the newspaper La Provence.
These translational studies have also enabled post-doctoral researcher Nicolas Fraunhoffer and the team led by Nelson Dusetti and their collaborators to establish transcriptomic signatures to personalize adjuvant chemotherapy in pancreatic adenocarcinoma (Publication: “Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma”).
And all the publications of the last few months that are advancing research
COMET Department
Team Bard :
Tomasini/Vasseur team:
“Predictive biomarkers for immune checkpoint efficacy: is multi-omics breaking the deadlock?”
Genome Integrity Department
Team Coulon :
“Heterozygous RPA2 variant as a novel genetic cause of telomere biology disorders”.
Team Llorente :
“Multiple independent losses of crossover interference during yeast evolutionary history”.
Team Modesti :
OHIO Department
Team Aurand-Lions :
Devillier / Nunes team :
“Targeting BTN2A1 enhances Vγ9Vδ2 T-cell effector functions and triggers tumor cell pyroptosis”.
“BTN2A1 targeting reprograms M2-like macrophages and TAMs via SYK and MAPK signaling”.
“Molecularly matched targeted therapy: a promising approach for refractory metastatic melanoma”.
Translate-it Department
Pasquier / André team :
Benzekry / Ciccolini team:
Team Iovanna / Dusetti :
Team Charafe-Jauffret :
“Brain metastases reirradiation.”
Bertucci / Mamessier team :
“Endometrioid ovarian carcinoma landscape: pathological and molecular characterization”.
All this work carried out at CRCM generates new knowledge and opens up new therapeutic perspectives for cancer patients.
